WO2009022185A3 - 6, 6-fused heterocycles, their pharmaceutical compositions and methos of use - Google Patents

6, 6-fused heterocycles, their pharmaceutical compositions and methos of use Download PDF

Info

Publication number
WO2009022185A3
WO2009022185A3 PCT/GB2008/050712 GB2008050712W WO2009022185A3 WO 2009022185 A3 WO2009022185 A3 WO 2009022185A3 GB 2008050712 W GB2008050712 W GB 2008050712W WO 2009022185 A3 WO2009022185 A3 WO 2009022185A3
Authority
WO
WIPO (PCT)
Prior art keywords
pharmaceutical compositions
treatment
relates
methos
bacterial
Prior art date
Application number
PCT/GB2008/050712
Other languages
French (fr)
Other versions
WO2009022185A2 (en
Inventor
Gloria Breault
Bolin Geng
Original Assignee
Astrazeneca Ab
Astrazeneca Uk Ltd
Gloria Breault
Bolin Geng
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab, Astrazeneca Uk Ltd, Gloria Breault, Bolin Geng filed Critical Astrazeneca Ab
Publication of WO2009022185A2 publication Critical patent/WO2009022185A2/en
Publication of WO2009022185A3 publication Critical patent/WO2009022185A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D475/00—Heterocyclic compounds containing pteridine ring systems
    • C07D475/06—Heterocyclic compounds containing pteridine ring systems with a nitrogen atom directly attached in position 4

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention relates to chemical compounds, or pharmaceutically acceptable salts thereof of the formula (I): which have bacterial Murl inhibitory activity and are accordingly useful for their treatment and prophylaxis of bacterial infection, e.g., E.faecalis or S.aureus infection. Further, the invention relates to methods of treatment of the human or animal body. The invention also relates to processes for the manufacture of the compounds, to pharmaceutical compositions containing them, and to their use in the manufacture of medicaments of use in the treatment and prevention of various bacterial diseases in a warm-blooded animal such as man.
PCT/GB2008/050712 2007-08-16 2008-08-15 6, 6-fused heterocycles, their pharmaceutical compositions and methos of use WO2009022185A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US95624807P 2007-08-16 2007-08-16
US60/956,248 2007-08-16

Publications (2)

Publication Number Publication Date
WO2009022185A2 WO2009022185A2 (en) 2009-02-19
WO2009022185A3 true WO2009022185A3 (en) 2009-07-09

Family

ID=40351224

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2008/050712 WO2009022185A2 (en) 2007-08-16 2008-08-15 6, 6-fused heterocycles, their pharmaceutical compositions and methos of use

Country Status (1)

Country Link
WO (1) WO2009022185A2 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA021377B9 (en) * 2008-12-09 2015-09-30 Джилид Сайэнс, Инк. Modulators of toll-like receptors
ES2661850T3 (en) 2009-09-14 2018-04-04 Gilead Sciences, Inc. Toll type receiver modulators
WO2012167046A1 (en) 2011-06-01 2012-12-06 Janus Biotherapeutics, Inc. Novel immune system modulators
WO2013071217A1 (en) * 2011-11-10 2013-05-16 OSI Pharmaceuticals, LLC Dihydropteridinones
WO2015160654A1 (en) * 2014-04-14 2015-10-22 Boehringer Ingelheim International Gmbh Compounds as modulators of ror gamma
TWI806081B (en) 2014-07-11 2023-06-21 美商基利科學股份有限公司 Modulators of toll-like receptors for the treatment of hiv
PT3194402T (en) 2014-09-16 2019-02-11 Gilead Sciences Inc Methods of preparing toll-like receptor modulators
UY36298A (en) 2014-09-16 2016-04-29 Gilead Science Inc SOLID FORMS OF A TOLL TYPE RECEIVER MODULATOR
WO2017219931A1 (en) * 2016-06-22 2017-12-28 四川科伦博泰生物医药股份有限公司 Dihydro pteridinone derivative, preparation method therefor, and application thereof
CN113831347B (en) * 2021-10-22 2022-10-04 广东海洋大学 6, 7-disubstituted 2- (ethylthio) -pteridine-4-amine derivative and preparation method and application thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0393400A1 (en) * 1989-03-31 1990-10-24 Wakunaga Seiyaku Kabushiki Kaisha Novel quinolone derivatives, preparation processes thereof, and antibacterial agents containing the same
WO2003024966A1 (en) * 2001-08-14 2003-03-27 Astrazeneca Ab Pteridinone derivatives as modulators of chemokine receptor activity

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0393400A1 (en) * 1989-03-31 1990-10-24 Wakunaga Seiyaku Kabushiki Kaisha Novel quinolone derivatives, preparation processes thereof, and antibacterial agents containing the same
WO2003024966A1 (en) * 2001-08-14 2003-03-27 Astrazeneca Ab Pteridinone derivatives as modulators of chemokine receptor activity

Also Published As

Publication number Publication date
WO2009022185A2 (en) 2009-02-19

Similar Documents

Publication Publication Date Title
WO2009022185A3 (en) 6, 6-fused heterocycles, their pharmaceutical compositions and methos of use
MX2007008924A (en) Chemical compounds.
TW200634003A (en) Chemical compounds
TW200635899A (en) Chemical compounds
TW200621259A (en) Chemical compounds
MX2009004908A (en) Chemical compounds.
WO2007113558A3 (en) Quinazolinone derivatives having b-raf inhibitory activity
WO2006087543A8 (en) Antibacterial piperidine derivatives
MY150958A (en) Compounds for the treatment of multi-drug resistant bacterial infections
MX2008013212A (en) 4-anilinoquinoline-3-carboxamides as csf-1r kinase inhibitors.
TW200736234A (en) Chemical compounds
TW200500358A (en) Compounds
MX2008013836A (en) 2-pyridone derivatives for the treatment of disease or condition in which inhibition of neutrophil elastase activity is beneficial.
WO2008020227A3 (en) Antibacterial pyrrolecarboxamides
SG170101A1 (en) 2-pyrazinone derivatives for the treatment of disease or condition in which inhibition of neutrophil elastase activity is beneficial.
WO2008020229A3 (en) Antibacterial pyrrolecarboxamides
MY148108A (en) Medicaments for the treatment or prevention of fibrotic diseases
TW200726748A (en) Chemical compounds II
MY181645A (en) Antibacterial quinoline derivatives
WO2007071965A3 (en) Antibacterial pyrrolopyridines, pyrrolopyrimidines, and pyrroloazepines
MX2009004561A (en) Pyrazolyl derivatives with analgesic activity and therefore useful in the treatment or prophylaxis of pain.
WO2007009721A3 (en) Indoline-substituted pyrazoline derivatives, their preparation and use as medicaments
WO2009030952A3 (en) Phenylcarboxamide derivatives as inhibitors and effectors of the hedgehog pathway
TNSN04203A1 (en) Benzoxazinone-derived compounds, their preparation and use as medicaments
WO2006108681A3 (en) Substances and pharmaceutical compositions for the inhibition of glyoxalases and their use against bacteria

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08788683

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08788683

Country of ref document: EP

Kind code of ref document: A2